文献速递乳腺癌

妊娠相关乳腺癌综述:临床特征、分子特征与新型治疗

Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
PubMed 文献 · Eur J Cancer · 2026-01-12

妊娠相关乳腺癌(PABC)包括妊娠期及产后第一年发生的乳腺癌和产后5-10年内发生的乳腺癌,约占所有乳腺癌的0.2-3.8%,发生率约1/3000妊娠。PABC常与三阴性亚型比例高、淋巴结受累多及晚期就诊等侵袭性临床生物学特征相关。本文综述乳腺生理变化与PABC癌变的关系、其分子谱与临床病理特征,并探讨胎儿安全性对治疗的限制及新型药物在妊娠期和哺乳期的安全性。

要点

  • PABC约占所有乳腺癌0.2-3.8%,发生率约1/3000妊娠
  • PABC更常见三阴性亚型、淋巴结受累及晚期表现
  • 分子特征包括增殖信号增强、代谢重编程、促瘤炎症及DNA损伤修复受损

核心结论

  • PABC具有侵袭性临床生物学特征,分子机制尚未完全明确,需妊娠兼容的新治疗策略。

研究设计与样本

  • 本文为综合性综述,检索并汇总PABC生理、分子及治疗相关文献。

主要发现

  • PABC常与三阴性亚型比例高、淋巴结受累多及晚期就诊相关。
  • 妊娠、哺乳及产后退化期乳腺微环境经历激素驱动的重塑,呈双相效应。
  • PABC分子谱显示增殖信号增强、代谢重编程、促瘤炎症及DNA损伤修复受损。
  • PABC与非妊娠相关乳腺癌基因组架构相似,但存在独特基因表达特征。

关键数值与推荐

  • PABC约占所有乳腺癌0.2-3.8%,发生率约1/3000妊娠。
  • PABC定义涵盖妊娠期及产后第一年(PrBC)和产后5-10年(PPBC)。

临床怎么用

  • 临床需认识PABC的侵袭性特征并关注胎儿安全性对治疗选择的限制。

局限性

  • PABC癌变的分子机制尚不完全清楚。
  • 新型治疗药物在妊娠期和哺乳期的安全性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pregnancy-Associated Breast Cancer (PABC) accounts for pregnancy-related breast cancer (PrBC), occurring during pregnancy and the first postpartum year, and postpartum breast cancer (PPBC), arising up to 5-10 years after childbirth. It represents an increasingly oncological challenge as delayed childbearing trends extend maternal reproductive age. Occurring in approximately 1:3000 pregnancies, PABC accounts for 0.2-3.8 % of all breast cancer cases. PABC is often associated with aggressive clinic-biological characteristics, including higher prevalence of triple-negative subtypes, increased lymph node involvement, and more frequent advanced-stage presentation compared to age-matched non-pregnant controls. The complex mammary microenvironment during pregnancy, lactation, and postpartum involution undergoes extensive hormonal-driven remodeling that creates a biphasic landscape, initially providing a permissive environment for carcinogenesis while conferring long-term protective effects. The molecular mechanisms underlying this transformation remain incompletely understood and represent an active area of investigation. Molecular profiling of PABC reveals enhanced proliferative signaling pathways, metabolic reprogramming, tumor-promoting inflammatory responses, and compromised DNA damage repair mechanisms. While PABC shares similar genomic architecture with non-pregnancy-associated breast cancers, distinct gene expression signatures have been identified that may contribute to its aggressive phenotype. This comprehensive review examines the physiological breast changes occurring throughout the reproductive cycle and their relationship to PABC carcinogenesis. We analyze the molecular profile and clinicopathological features that distinguish PABC from conventional breast cancer, while addressing the therapeutic challenges posed by fetal safety considerations. Additionally, we evaluate the safety profiles of novel therapeutic agents during pregnancy and lactation, highlighting the critical need for new pregnancy-compatible treatment strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Spata A, Ribeiro JM, Vigneri P, et al. Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies. Eur J Cancer. 2026. PMID: 41547179. doi:10.1016/j.ejca.2026.116230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。